HLA Class I markers in Japanese patients with carbamazepine‐induced cutaneous adverse reactions

Summary Carbamazepine (CBZ) is frequently used for treating epilepsy, but this drug causes cutaneous adverse drug reactions (cADRs) that may range from mild to severe. It is reported recently that the human leukocyte antigen HLA‐B*1502 is associated with Stevens‐Johnson syndrome (SJS) induced by CBZ...

Full description

Saved in:
Bibliographic Details
Published in:Epilepsia (Copenhagen) 2010-02, Vol.51 (2), p.297-300
Main Authors: Ikeda, Hiroko, Takahashi, Yukitoshi, Yamazaki, Etsuko, Fujiwara, Tateki, Kaniwa, Nahoko, Saito, Yoshiro, Aihara, Michiko, Kashiwagi, Mariko, Muramatsu, Masaaki
Format: Article
Language:English
Subjects:
Adolescent
Adult
Alleles
Asian Continental Ancestry Group - genetics
Carbamazepine
Carbamazepine - adverse effects
Carbamazepine - therapeutic use
Child
Cutaneous adverse drug reactions
Drug Eruptions - diagnosis
Drug Eruptions - epidemiology
Drug Eruptions - etiology
Drug Hypersensitivity - genetics
Epilepsy - drug therapy
Epilepsy - genetics
Female
Gene Frequency
Genetic Markers
Haplotypes - genetics
Histocompatibility Antigens Class I - genetics
HLA Antigens - genetics
HLA class I
HLA-B Antigens - genetics
HLA-B52 Antigen
HLA‐B5901
Humans
Infant
Male
Middle Aged
Pharmacogenetics
Risk Factors
Stevens-Johnson Syndrome - chemically induced
Stevens-Johnson Syndrome - diagnosis
Stevens-Johnson Syndrome - genetics
Stevens‐Johnson syndrome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Carbamazepine (CBZ) is frequently used for treating epilepsy, but this drug causes cutaneous adverse drug reactions (cADRs) that may range from mild to severe. It is reported recently that the human leukocyte antigen HLA‐B*1502 is associated with Stevens‐Johnson syndrome (SJS) induced by CBZ in Han Chinese. We examined HLA class I in 15 Japanese patients who fulfilled the diagnostic criteria for CBZ‐induced cADRs (mild in 10 and severe = SJS in 5). HLA‐B*1518, HLA‐B*5901 and HLA‐C*0704 alleles showed higher relative risks (above 10.0) for severe cADRs. The haplotype (HLA‐A*2402‐B*5901‐C*0102) had high relative risk (16.09) for severe cADRs. In patients with severe cADRs, frequencies of HLA‐A*1101, HLA‐A*3303, HLA‐B*1501, HLA‐B*4403, HLA‐B*5101, HLA‐B*5201, HLA‐C*0702, and HLA‐C*1202 alleles are relatively lower than in the Japanese population. These data may suggest that HLA‐B*5901 is one of the candidate markers for CBZ‐induced SJS in Japanese.
ISSN:0013-9580
1528-1167
DOI:10.1111/j.1528-1167.2009.02269.x